Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

TUSTIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has been enrolled and patients are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label study is to assess the overall tumor response to the regimen of bavituximab in combination with carboplatin/paclitaxel. Separately, the company announced issuance of a new U.S. patent with claims covering the use of bavituximab in combination with a broad range of cancer therapeutic agents. Peregrine is currently conducting three separate Phase II studies testing bavituximab in combination with docetaxel or carboplatin and paclitaxel in advanced breast and lung cancer patients. These combination therapies, which have shown promising initial results, are all covered under the claims in the newly issued patent.

"It is fitting that this new U.S. patent protecting the use of bavituximab in combination with a variety of anti-cancer therapeutics has issued as enrollment in each of our three Phase II trials of bavituximab in combination with chemotherapy is either completed or nearing completion," said Steven W. King, president and CEO of Peregrine. "There is considerable evidence that bavituximab and other anti-PS antibodies act synergistically with standard cancer treatments, and the additional protection provided by this new patent further strengthens our intellectual property leadership in the field of PS-targeting therapeutics."

U.S. Patent #7,572,448 covers the therapeutic use of bavituximab and rela
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, ... today announced that it will host a webcast on June 8, ... 6th at the 14th Congress of the European Hematology Association. ... www.micromet-inc.com . , , Forum: ...
... VIEW, Calif., June 2 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and ... featured in two podium presentations during the 69th Scientific ... from June 5-9, 2009 in New Orleans, Louisiana. ...
... June 2 BioGenex, a developer of innovative instruments ... molecular diagnostics, announced today that Abbott has entered into ... distribution agreement to market the Xmatrx(R) platform for the ... terms of the agreement Abbott customers will have the ...
Cached Biology Technology:Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 3Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 4Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 2Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 3Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... study funded by the New Jersey Recovery Fund and ... of Planning and Public Policy at Rutgers University has ... skeptical about the likelihood of community-based rebuilding solutions. Of ... indicated they were "pessimistic" or "very pessimistic" that the ... be rebuilt better than they were before the storm; ...
(Date:7/24/2014)... life arose have been maintained in our cells today according ... published today in the Journal of Biological Chemistry ... in animals still perform ancient reactions thought to have been ... years ago. , The primordial soup theory suggests that life ... the combination of metals, gases from the atmosphere and some ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... reported preclinical study results, which demonstrate the ... cells (ADRCs) for the treatment of damaged ... tissue density and disc-specific extracellular matrix components ... animal model. The data were presented today ...
... Society (ACS) News Service Weekly PressPac with news from ACS, ... credit the individual journal or the American Chemical Society as ... IMMEDIATE RELEASE EXCEPT ARTICLE #5, which is embargoed for 9 ... PressPac Archive: ARTICLE ...
... and abnormalities in metabolism and diabetes has been suggested in ... Oxford, the Wellcome Trust Sanger Institute and the MRC Epidemiology ... involved in the way the body responds to the 24 ... sugar levels and an increased risk of type 2 diabetes. ...
Cached Biology News:Cytori reports benefit of adipose-derived regenerative cells in spinal disc model 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 3American Chemical Society's Weekly PressPac -- Dec. 3, 2008 4American Chemical Society's Weekly PressPac -- Dec. 3, 2008 5American Chemical Society's Weekly PressPac -- Dec. 3, 2008 6American Chemical Society's Weekly PressPac -- Dec. 3, 2008 7American Chemical Society's Weekly PressPac -- Dec. 3, 2008 8Discovery of new gene associated with diabetes risk suggests link with body clock 2
... DASGIP Overhead Drive for individual and ... for flexible agitation of DASGIP vessels, featuring ... impellers. ,Up to 16 overhead drives ... DASGIP Cultivation Systems fedbatch-pro® and cellferm-pro® for ...
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The system is especially dedicated ... standard system for Western blotting applications.,Fuiji's ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... the space and time dimensions of a streak ... microscope to open new horizons in biological imaging. ... excitation, the decay of a fluorescence emission can ... measured. Subtle changes in the local environment ...
Biology Products: